{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T16:18:39Z","timestamp":1786378719957,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T00:00:00Z","timestamp":1358294400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Marked hyperphosphatemia, hyperparathyroidism and 25-hydroxyvitamin D deficiency are associated with mortality in dialysis patients. Such data in chronic kidney disease stage 2\u20134 population are limited. It has been suggested that high-normal serum phosphate predicts worse renal and patient outcomes. The data regarding parathyroid hormone and outcomes in this population is limited. The present study examined mineral metabolism and its association with the development of end-stage renal disease and mortality in stage 2\u20134 chronic kidney disease patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>This is a prospective cohort study that included 466 non-dialysis chronic kidney disease stage 2\u20134 patients. Mineral parameters were obtained at the time of enrollment and the patients were followed prospectively for 25 (1\u201344) months or until they reached the endpoints of end-stage renal disease or mortality.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Hyperparathyroidism and 25-hydroxyvitamin D deficiency began to occur in the early stages of chronic kidney disease, whereas significant hyperphosphatemia only developed in the later stages. High-normal and mildly elevated serum phosphate (&gt;4.2 mg\/dL) predicted the composite outcome of end-stage renal disease or mortality after adjustments for cardiovascular risk factors, chronic kidney disease stage and other mineral parameters. Parathyroid hormone levels above the upper limit of normal (&gt;65 pg\/mL) predicted the future development of end-stage renal disease and the composite outcome of end-stage renal disease or mortality after adjustments. 25-hydroxyvitamin D deficiency (&lt;15 ng\/mL) was also associated with worse outcomes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>In chronic kidney disease, hyperparathyroidism developed prior to significant hyperphosphatemia confirming the presence phosphate retention early in the course of chronic kidney disease. High-normal serum phosphate and mildly elevated parathyroid hormone levels predicted worse renal and patient outcomes. This data emphasizes the need for early intervention in the care of chronic kidney disease stage 2\u20134 patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2369-14-14","type":"journal-article","created":{"date-parts":[[2013,1,16]],"date-time":"2013-01-16T13:14:50Z","timestamp":1358342090000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Mineral metabolism and outcomes in chronic kidney disease stage 2\u20134 patients"],"prefix":"10.1186","volume":"14","author":[{"given":"Kamonwan","family":"Chartsrisak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotcharat","family":"Vipattawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montira","family":"Assanatham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arkom","family":"Nongnuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atiporn","family":"Ingsathit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnuek","family":"Domrongkitchaiporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasant","family":"Sumethkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinee","family":"Distha-Banchong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,16]]},"reference":[{"issue":"5","key":"426_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1001\/jama.2010.39","volume":"303","author":"BR Hemmelgarn","year":"2010","unstructured":"Hemmelgarn BR, Manns BJ, Lloyd A, James MT, Klarenbach S, Quinn RR, Wiebe N, Tonelli M, Alberta Kidney Disease N: Relation between kidney function, proteinuria, and adverse outcomes. JAMA. 2010, 303 (5): 423-429. 10.1001\/jama.2010.39.","journal-title":"JAMA"},{"issue":"8","key":"426_CR2","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","volume":"15","author":"GA Block","year":"2004","unstructured":"Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004, 15 (8): 2208-2218. 10.1097\/01.ASN.0000133041.27682.A2.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"426_CR3","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","volume":"26","author":"J Floege","year":"2011","unstructured":"Floege J, Kim J, Ireland E, Chazot C, Drueke T, de Francisco A, Kronenberg F, Marcelli D, Passlick-Deetjen J, Schernthaner G, et al: Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant. 2011, 26 (6): 1948-1955. 10.1093\/ndt\/gfq219.","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"426_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/sj.ki.5002009","volume":"71","author":"A Levin","year":"2007","unstructured":"Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL: Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007, 71 (1): 31-38. 10.1038\/sj.ki.5002009.","journal-title":"Kidney Int"},{"issue":"12","key":"426_CR5","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/ki.2011.47","volume":"79","author":"T Isakova","year":"2011","unstructured":"Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, et al: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011, 79 (12): 1370-1378. 10.1038\/ki.2011.47.","journal-title":"Kidney Int"},{"issue":"2","key":"426_CR6","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1681\/ASN.2004070602","volume":"16","author":"B Kestenbaum","year":"2005","unstructured":"Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2005, 16 (2): 520-528. 10.1681\/ASN.2004070602.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"426_CR7","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1093\/ndt\/gfq309","volume":"25","author":"S Seiler","year":"2010","unstructured":"Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH: FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010, 25 (12): 3983-3989. 10.1093\/ndt\/gfq309.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"426_CR8","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/ndt\/gfm286","volume":"22","author":"N Voormolen","year":"2007","unstructured":"Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, Huisman RM, Krediet RT, Dekker FW, et al: High plasma phosphate as a risk factor for decline in renal function and mortality in pre-dialysis patients. Nephrol Dial Transplant. 2007, 22 (10): 2909-2916. 10.1093\/ndt\/gfm286.","journal-title":"Nephrol Dial Transplant"},{"issue":"9","key":"426_CR9","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1093\/ndt\/gfq815","volume":"26","author":"K Praditpornsilpa","year":"2011","unstructured":"Praditpornsilpa K, Townamchai N, Chaiwatanarat T, Tiranathanagul K, Katawatin P, Susantitaphong P, Trakarnvanich T, Kanjanabuch T, Avihingsanon Y, Tungsanga K, et al: The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant. 2011, 26 (9): 2780-2785. 10.1093\/ndt\/gfq815.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"426_CR10","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","volume":"31","author":"GA Block","year":"1998","unstructured":"Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998, 31 (4): 607-617. 10.1053\/ajkd.1998.v31.pm9531176.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"426_CR11","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1681\/ASN.2004040275","volume":"16","author":"Y Slinin","year":"2005","unstructured":"Slinin Y, Foley RN, Collins AJ: Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol. 2005, 16 (6): 1788-1793. 10.1681\/ASN.2004040275.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"426_CR12","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1523-1755.2005.00185.x","volume":"67","author":"EW Young","year":"2005","unstructured":"Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, et al: Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005, 67 (3): 1179-1187. 10.1111\/j.1523-1755.2005.00185.x.","journal-title":"Kidney Int"},{"issue":"5","key":"426_CR13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","volume":"24","author":"A Covic","year":"2009","unstructured":"Covic A, Kothawala P, Bernal M, Robbins S, Chalian A, Goldsmith D: Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrol Dial Transplant. 2009, 24 (5): 1506-1523. 10.1093\/ndt\/gfn613.","journal-title":"Nephrol Dial Transplant"},{"issue":"7","key":"426_CR14","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1681\/ASN.2005010052","volume":"16","author":"O Gutierrez","year":"2005","unstructured":"Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M: Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005, 16 (7): 2205-2215. 10.1681\/ASN.2005010052.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"426_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/ki.2009.76","volume":"76","author":"P Muntner","year":"2009","unstructured":"Muntner P, Vupputuri S, Coresh J, Uribarri J, Fox CS: Metabolic abnormalities are present in adults with elevated serum cystatin C. Kidney Int. 2009, 76 (1): 81-88. 10.1038\/ki.2009.76.","journal-title":"Kidney Int"},{"issue":"4","key":"426_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2215\/CJN.07810910","volume":"6","author":"A Bellasi","year":"2011","unstructured":"Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G, Santoro A: Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction. Clin J Am Soc Nephrol. 2011, 6 (4): 883-891. 10.2215\/CJN.07810910.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"17","key":"426_CR17","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1161\/CIRCULATIONAHA.105.553198","volume":"112","author":"M Tonelli","year":"2005","unstructured":"Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G: Cholesterol, Recurrent Events Trial I: Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005, 112 (17): 2627-2633. 10.1161\/CIRCULATIONAHA.105.553198.","journal-title":"Circulation"},{"issue":"4","key":"426_CR18","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.amjmed.2008.09.039","volume":"122","author":"M Chonchol","year":"2009","unstructured":"Chonchol M, Dale R, Schrier RW, Estacio R: Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med. 2009, 122 (4): 380-386. 10.1016\/j.amjmed.2008.09.039.","journal-title":"Am J Med"},{"issue":"9","key":"426_CR19","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1001\/archinte.167.9.879","volume":"167","author":"R Dhingra","year":"2007","unstructured":"Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB, Gaziano JM, Vasan RS: Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007, 167 (9): 879-885. 10.1001\/archinte.167.9.879.","journal-title":"Arch Intern Med"},{"issue":"3","key":"426_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.ahj.2008.05.016","volume":"156","author":"RN Foley","year":"2008","unstructured":"Foley RN, Collins AJ, Ishani A, Kalra PA: Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008, 156 (3): 556-563. 10.1016\/j.ahj.2008.05.016.","journal-title":"Am Heart J"},{"issue":"6","key":"426_CR21","doi-asserted-by":"publisher","first-page":"F1381","DOI":"10.1152\/ajprenal.00003.2008","volume":"294","author":"GS Di Marco","year":"2008","unstructured":"Di Marco GS, Hausberg M, Hillebrand U, Rustemeyer P, Wittkowski W, Lang D, Pavenstadt H: Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol. 2008, 294 (6): F1381-F1387. 10.1152\/ajprenal.00003.2008.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"7","key":"426_CR22","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1681\/ASN.2008101106","volume":"20","author":"E Shuto","year":"2009","unstructured":"Shuto E, Taketani Y, Tanaka R, Harada N, Isshiki M, Sato M, Nashiki K, Amo K, Yamamoto H, Higashi Y, et al: Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol. 2009, 20 (7): 1504-1512. 10.1681\/ASN.2008101106.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"426_CR23","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.2215\/CJN.02420409","volume":"4","author":"JF Navarro-Gonzalez","year":"2009","unstructured":"Navarro-Gonzalez JF, Mora-Fernandez C, Muros M, Herrera H, Garcia J: Mineral metabolism and inflammation in chronic kidney disease patients: a cross-sectional study. Clin J Am Soc Nephrol. 2009, 4 (10): 1646-1654. 10.2215\/CJN.02420409.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"22","key":"426_CR24","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/eurheartj\/ehs152","volume":"33","author":"S Shin","year":"2012","unstructured":"Shin S, Kim KJ, Chang HJ, Cho I, Kim YJ, Choi BW, Rhee Y, Lim SK, Yang WI, Shim CY, et al: Impact of serum calcium and phosphate on coronary atherosclerosis detected by cardiac computed tomography. Eur Heart J. 2012, 33 (22): 2873-2881. 10.1093\/eurheartj\/ehs152.","journal-title":"Eur Heart J"},{"issue":"6","key":"426_CR25","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Juppner H, et al: Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008, 359 (6): 584-592. 10.1056\/NEJMoa0706130.","journal-title":"N Engl J Med"},{"issue":"23","key":"426_CR26","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1001\/jama.2011.826","volume":"305","author":"T Isakova","year":"2011","unstructured":"Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutierrez OM, Steigerwalt S, He J, et al: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011, 305 (23): 2432-2439. 10.1001\/jama.2011.826.","journal-title":"JAMA"},{"issue":"11","key":"426_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1038\/ki.2008.64","volume":"73","author":"CP Kovesdy","year":"2008","unstructured":"Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K: Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008, 73 (11): 1296-1302. 10.1038\/ki.2008.64.","journal-title":"Kidney Int"},{"issue":"9","key":"426_CR28","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, et al: Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007, 18 (9): 2600-2608. 10.1681\/ASN.2006080936.","journal-title":"J Am Soc Nephrol"},{"issue":"19","key":"426_CR29","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, et al: Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009, 119 (19): 2545-2552. 10.1161\/CIRCULATIONAHA.108.844506.","journal-title":"Circulation"},{"issue":"10","key":"426_CR30","doi-asserted-by":"publisher","first-page":"640","DOI":"10.7326\/0003-4819-152-10-201005180-00004","volume":"152","author":"BD Parker","year":"2010","unstructured":"Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH: The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010, 152 (10): 640-648.","journal-title":"Ann Intern Med"},{"issue":"6","key":"426_CR31","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1161\/HYPERTENSIONAHA.111.179135","volume":"58","author":"R Deo","year":"2011","unstructured":"Deo R, Katz R, Shlipak MG, Sotoodehnia N, Psaty BM, Sarnak MJ, Fried LF, Chonchol M, de Boer IH, Enquobahrie D, et al: Vitamin D, parathyroid hormone, and sudden cardiac death: results from the Cardiovascular Health Study. Hypertension. 2011, 58 (6): 1021-1028. 10.1161\/HYPERTENSIONAHA.111.179135.","journal-title":"Hypertension"},{"issue":"11","key":"426_CR32","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1097\/00004872-199715110-00011","volume":"15","author":"L Morfis","year":"1997","unstructured":"Morfis L, Smerdely P, Howes LG: Relationship between serum parathyroid hormone levels in the elderly and 24 h ambulatory blood pressures. J Hypertens. 1997, 15 (11): 1271-1276. 10.1097\/00004872-199715110-00011.","journal-title":"J Hypertens"},{"issue":"6","key":"426_CR33","doi-asserted-by":"publisher","first-page":"3326","DOI":"10.1210\/jc.2004-1400","volume":"90","author":"MR Rubin","year":"2005","unstructured":"Rubin MR, Maurer MS, McMahon DJ, Bilezikian JP, Silverberg SJ: Arterial stiffness in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2005, 90 (6): 3326-3330. 10.1210\/jc.2004-1400.","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"426_CR34","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1093\/cvr\/cvs092","volume":"94","author":"A Tomaschitz","year":"2012","unstructured":"Tomaschitz A, Ritz E, Pieske B, Fahrleitner-Pammer A, Kienreich K, Horina JH, Drechsler C, Marz W, Ofner M, Pieber TR, et al: Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012, 94 (1): 10-19. 10.1093\/cvr\/cvs092.","journal-title":"Cardiovasc Res"},{"issue":"9","key":"426_CR35","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1038\/ki.2009.288","volume":"76","author":"R Mehrotra","year":"2009","unstructured":"Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC: Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009, 76 (9): 977-983. 10.1038\/ki.2009.288.","journal-title":"Kidney Int"},{"issue":"4","key":"426_CR36","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1053\/j.ajkd.2011.04.028","volume":"58","author":"SD Navaneethan","year":"2011","unstructured":"Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Jain A, Schreiber MJ, Simon JF, Srinivas TR, Nally JV: Low 25-hydroxyvitamin D levels and mortality in non-dialysis-dependent CKD. Am J Kidney Dis. 2011, 58 (4): 536-543. 10.1053\/j.ajkd.2011.04.028.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"426_CR37","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/ki.2008.501","volume":"75","author":"P Ravani","year":"2009","unstructured":"Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C: Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009, 75 (1): 88-95. 10.1038\/ki.2008.501.","journal-title":"Kidney Int"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2369-14-14\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2369-14-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T21:30:04Z","timestamp":1630531804000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/1471-2369-14-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,16]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["426"],"URL":"https:\/\/doi.org\/10.1186\/1471-2369-14-14","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,16]]},"assertion":[{"value":"21 June 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}